Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals announced its participation in the Canaccord Genuity 46th Annual Growth Conference where it will present its latest developments. The company focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its drug Rezdiffra already approved in the US and Europe for treating MASH with mo…